Walker May
Family Medicine · Vivian, LANPI 1003083205
Payments from drug & device makers
Across 93 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$696
- Lilly USA, LLC$144
- GSK$120
- Astellas Pharma US Inc$111
- Pfizer$101
- Melinta Therapeutics, LLC$94
- plus $450 from 15 others
What the payments were for
- Food & beverage$1,57692%
- Education$1408%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 35 | $696 |
| Lilly USA, LLC | 8 | $144 |
| GSK | 7 | $120 |
| Astellas Pharma US Inc | 2 | $111 |
| Pfizer | 7 | $101 |
| Melinta Therapeutics, LLC | 6 | $94 |
| Boehringer Ingelheim | 5 | $82 |
| Novo Nordisk | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Mylan Specialty L.p. | 2 | $46 |
| AstraZeneca | 3 | $43 |
| Exact Sciences | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Bayer | 1 | $21 |
| Insulet Corporation | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Organogenesis Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Inogen, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$125
How this compares
$1,716 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $142,754 |
| EliquisApixaban | 48 | $78,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $78,296 |
| JardianceEmpagliflozin | 37 | $51,661 |
| FarxigaDapagliflozin Propanediol | 26 | $39,418 |
| MyrbetriqMirabegron | 33 | $29,359 |
| MounjaroTirzepatide | 24 | $28,798 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $22,042 |
| JanuviaSitagliptin Phosphate | 13 | $21,692 |
| TrulicityDulaglutide | 11 | $17,606 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $17,061 |
| VascepaIcosapent Ethyl | 20 | $16,331 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $14,034 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $13,679 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $12,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $54 | $142,75493 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $120 | $100,53695 claims |
| PfizerEliquis | $101 | $78,87148 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $82 | $68,72249 claims |
| Lilly USA, LLCMounjaro, Trulicity | $144 | $46,40335 claims |
| AstraZenecaFarxiga | $43 | $39,41826 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $29,35933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Vivian
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.